Long-Term (>3 Years) Outcome and Predictors of Clinical Events After Insertion of Sirolimus-Eluting Stent in One or More Native Coronary Arteries (from the Israeli Arm of the e-Cypher Registry)

American Journal of Cardiology

Volumn 101, Issue 7, 2008, Pages 953-959

  Planer, David ^a   Beyar, Rafael ^b   Almagor, Yaron ^c   Banai, Shmuel ^d   Guetta, Victor ^e   Miller, Hilton ^f   Kornowski, Ran ^g   Brandes, Simcha ^h   Krakover, Ricardo ⁱ   Solomon, Mivi ^j   Lotan, Chaim ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d BIKUR CHOLIM HOSPITAL   (Israel)

^e SHEBA MEDICAL CENTER   (Israel)

^f TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^g RABIN MEDICAL CENTER   (Israel)

^h LANIADO HOSPITAL   (Israel)

ⁱ ASSAF HAROFEH MEDICAL CENTER   (Israel)

^j Israel Heart Society   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAPAMYCIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISRAEL; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOMES RESEARCH; POSTMARKETING SURVEILLANCE; PREDICTION; PRIORITY JOURNAL; THROMBOSIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISRAEL; MALE; MIDDLE AGED; REGISTRIES; SIROLIMUS; SURVIVAL ANALYSIS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 41049093247     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.11.043     Document Type: Article

References (26)

1. Urban P., Gershlick A.H., Guagliumi G., Guyon P., Lotan C., Schofer J., Seth A., Sousa J.E., Wijns W., Berge C., et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 113 (2006) 1434-1441
2. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
3. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Vaina S., Morger C., Kukreja N., Juni P., Sianos G., Hellige G., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
4. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
5. Cordis Corporation. Cypher® sirolimus-eluting coronary stent-essential prescribing information. http://www.cordis.com/active/crdus/en_US/html/cordis/downloads/CYPHER_EP I_1551787_4.pdf Accessed on June 15, 2007
6. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
7. Ako J., Morino Y., Honda Y., Hassan A., Sonoda S., Yock P.G., Leon M.B., Moses J.W., Bonneau H.N., and Fitzgerald P.J. Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. J Am Coll Cardiol 46 (2005) 1002-1005
8. Moreno R., Fernandez C., Hernandez R., Alfonso F., Angiolillo D.J., Sabate M., Escaned J., Banuelos C., Fernandez-Ortiz A., and Macaya C. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45 (2005) 954-959
9. Luscher T.F., Steffel J., Eberli F.R., Joner M., Nakazawa G., Tanner F.C., and Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
10. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., Airoldi F., Chieffo A., Montorfano M., Carlino M., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
11. Kuchulakanti P.K., Chu W.W., Torguson R., Ohlmann P., Rha S.W., Clavijo L.C., Kim S.W., Bui A., Gevorkian N., Xue Z., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
12. Amann K., and Ritz E. Cardiac disease in chronic uremia: pathophysiology. Adv Ren Replace Ther 4 (1997) 212-224
13. Rubenstein M.H., Harrell L.C., Sheynberg B.V., Schunkert H., Bazari H., and Palacios I.F. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era?. Circulation 102 (2000) 2966-2972
14. Ong A.T., Hoye A., Aoki J., van Mieghem C.A., Rodriguez Granillo G.A., Sonnenschein K., Regar E., McFadden E.P., Sianos G., van der Giessen W.J., et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 45 (2005) 947-953
15. Rao S.V., Shaw R.E., Brindis R.G., Klein L.W., Weintraub W.S., and Peterson E.D. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol 97 (2006) 1478-1481
16. Shuchman M. Debating the risks of drug-eluting stents. N Engl J Med 356 (2007) 325-328
17. Win H.K., Caldera A.E., Maresh K., Lopez J., Rihal C.S., Parikh M.A., Granada J.F., Marulkar S., Nassif D., Cohen D.J., and Kleiman N.S. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (2007) 2001-2009
18. Beohar N., Davidson C.J., Kip K.E., Goodreau L., Vlachos H.A., Meyers S.N., Benzuly K.H., Flaherty J.D., Ricciardi M.J., Bennett C.L., and Williams D.O. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297 (2007) 1992-2000
19. Grines C.L., Bonow R.O., Casey Jr. D.E., Gardner T.J., Lockhart P.B., Moliterno D.J., O'Gara P., and Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115 (2007) 813-818
20. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., Rickenbacher P., Hunziker P., Mueller C., Jeger R., Bader F., Osswald S., and Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
21. Spertus J.A., Kettelkamp R., Vance C., Decker C., Jones P.G., Rumsfeld J.S., Messenger J.C., Khanal S., Peterson E.D., Bach R.G., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
22. Eisenstein E.L., Anstrom K.J., Kong D.F., Shaw L.K., Tuttle R.H., Mark D.B., Kramer J.M., Harrington R.A., Matchar D.B., Kandzari D.E., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
23. Serruys P.W., and Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents?. Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation 115 (2007) 1433-1439
24. Stone G.W., Moses J.W., Ellis S.G., Schofer J., Dawkins K.D., Morice M.C., Colombo A., Schampaert E., Grube E., Kirtane A.J., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
25. Stettler C., Wandel S., Allemann S., Kastrati A., Morice M.C., Schomig A., Pfisterer M.E., Stone G.W., Leon M.B., de Lezo J.S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
26. Kastrati A., Mehilli J., Pache J., Kaiser C., Valgimigli M., Kelbaek H., Menichelli M., Sabate M., Suttorp M.J., Baumgart D., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039